BofA’s Hartnett says concentrated U.S. stock returns are likely to persist
Andrew D. Dickinson, Chief Financial Officer of GILEAD SCIENCES, INC. (NASDAQ:GILD), sold 2,500 shares of common stock on July 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $111.03, for a total transaction value of $277,575. GILEAD, a prominent player in the Biotechnology industry with a market capitalization of $136.65 billion, has demonstrated strong performance with a 57% return over the past year. According to InvestingPro analysis, the stock currently trades below its Fair Value, suggesting potential upside opportunity.
Following the transaction, Dickinson directly owns 162,610 shares of GILEAD SCIENCES, INC. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. The company maintains a solid financial position with a "GREAT" health score and has consistently raised its dividend for 10 consecutive years, currently yielding 2.9%. Discover more insights about GILEAD’s financial health and growth potential in the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Gilead Sciences has announced promising Phase 3 data for its twice-yearly HIV prevention injection, Yeztugo (lenacapavir), showing efficacy across diverse groups, including pregnant women and adolescents. The U.S. Food and Drug Administration has approved Yeztugo as the first twice-yearly HIV prevention option, marking a significant advancement in pre-exposure prophylaxis (PrEP) treatments. Bernstein has reiterated an Outperform rating on Gilead, highlighting Yeztugo’s growth potential and projecting $6.6 billion in PrEP revenue by 2030. The firm notes that achieving insurance formulary adoption will be crucial for an accelerated launch. Additionally, Gilead has partnered with Kymera Therapeutics to develop a novel cancer drug targeting CDK2, with Kymera potentially receiving up to $750 million in payments. This collaboration aims to create more precise cancer treatments by removing the CDK2 protein. BMO Capital has also reiterated an Outperform rating on Gilead, emphasizing the commercial potential of Yeztugo based on strong clinical data. Gilead’s recent developments position it strategically in both the HIV prevention and cancer treatment markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.